- Home
- CRMD vs GERN Comparison
CRMD vs GERN Comparison
Compare CRMD & GERN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRMD
- GERN
- Stock Information
- Founded
- CRMD 2006
- GERN 1990
- Country
- CRMD United States
- GERN United States
- Employees
- CRMD N/A
- GERN N/A
- Industry
- CRMD Biotechnology: Pharmaceutical Preparations
- GERN Biotechnology: Pharmaceutical Preparations
- Sector
- CRMD Health Care
- GERN Health Care
- Exchange
- CRMD Nasdaq
- GERN Nasdaq
- Market Cap
- CRMD 925.6M
- GERN 823.0M
- IPO Year
- CRMD 2010
- GERN 1996
- Fundamental
- Price
- CRMD $12.94
- GERN $1.27
- Analyst Decision
- CRMD Strong Buy
- GERN Buy
- Analyst Count
- CRMD 8
- GERN 8
- Target Price
- CRMD $17.57
- GERN $3.71
- AVG Volume (30 Days)
- CRMD 4.6M
- GERN 6.4M
- Earning Date
- CRMD 10-29-2025
- GERN 11-06-2025
- Dividend Yield
- CRMD N/A
- GERN N/A
- EPS Growth
- CRMD N/A
- GERN N/A
- EPS
- CRMD 0.79
- GERN N/A
- Revenue
- CRMD $121,484,498.00
- GERN $164,447,000.00
- Revenue This Year
- CRMD $404.81
- GERN $175.15
- Revenue Next Year
- CRMD $56.11
- GERN $56.61
- P/E Ratio
- CRMD $16.35
- GERN N/A
- Revenue Growth
- CRMD 14970.29
- GERN 11877.20
- 52 Week Low
- CRMD $5.60
- GERN $1.09
- 52 Week High
- CRMD $17.43
- GERN $4.83
- Technical
- Relative Strength Index (RSI)
- CRMD 49.60
- GERN 40.76
- Support Level
- CRMD $12.73
- GERN $1.27
- Resistance Level
- CRMD $13.83
- GERN $1.52
- Average True Range (ATR)
- CRMD 0.75
- GERN 0.06
- MACD
- CRMD -0.16
- GERN -0.02
- Stochastic Oscillator
- CRMD 40.24
- GERN 0.00
About CRMD CorMedix Inc.
Cormedix Inc is a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions. The Company's focus is on the commercialization of its product, DefenCath, in the United States (U.S.) and other key markets. The group currently operates in a single segment, Drug Product, located in a single geographic location, the United States.
About GERN Geron Corporation
Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses various rights to this drug. The company operates as a single segment being, the development of therapeutic products for oncology.